Publications by authors named "J Marksteiner"
Alzheimer's disease (AD) is a neurodegenerative disease characterized by memory loss and progressive deterioration of cognitive functions. Being able to identify reliable biomarkers in easily available body fluids such as blood plasma is vital for the disease. To achieve this, we used a technique that applied human plasma to organotypic brain slice culture via microcontact printing.
View Article and Find Full Text PDFCombined cognitive assessment and automated MRI volumetry improves the diagnostic accuracy of detecting MCI due to Alzheimer's disease.
Prog Neuropsychopharmacol Biol Psychiatry
September 2024
Background: Mild cognitive impairment (MCI) confers a high annual risk of 10-15 % of conversion to Alzheimer's disease (AD) dementia. MRI atrophy patterns derived from automated ROI analysis, particularly hippocampal subfield volumes, were reported to be useful in diagnosing early clinical stages of Alzheimer's disease.
Objective: The aim of the present study was to combine automated ROI MRI morphometry of hippocampal subfield volumes and cortical thickness estimates using FreeSurfer 6.
Alzheimer's disease is a severe neurodegenerative disorder, and the discovery of biomarkers is crucial for early diagnosis. While the analysis of biomarkers in cerebrospinal fluid is well accepted, there are currently no blood biomarkers available. Our research focuses on identifying novel plasma biomarkers for Alzheimer's disease.
View Article and Find Full Text PDFInvestigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population.
BJPsych Open
September 2024
Article Synopsis
- - The study evaluated the real-world applicability of lecanemab, a newly FDA-approved monoclonal antibody for Alzheimer's-related dementia, by analyzing data from a memory clinic between January 2022 and July 2023.
- - Out of 587 out-patients, only 4.3% with dementia and 1.5% with mild cognitive impairment (MCI) qualified for lecanemab treatment based on its eligibility criteria, while a notable percentage of others lacked necessary amyloid status.
- - Findings indicate that despite having a specialized clinic dedicated to dementia diagnostics, the majority of patients do not qualify for lecanemab, highlighting challenges in applying clinical trial criteria to real-world populations.
Background: The COVID-19 pandemic has had an unparalleled impact, precipitating not only direct threats to physical health but also widespread economic and psychological challenges. This study aims to explore the dynamics of coping behaviour and psychological distress (PD) across different phases of the pandemic within an adult general population sample, spanning Austria and Italy.
Methods: An online questionnaire-based panel study was conducted between 2020 and 2023 including three measurements.